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Abstract
Background The development of erythropoiesis-stimulat-
ing agents (ESAs) with extended serum half-lives has
allowed marked prolongation of the administration intervals.
The level of oxidative stress is increased in chronic kidney
disease, and is reportedly decreased after long-term ESA
treatment. However, the effect of different dosing regimens
of ESAs on oxidative stress has not been elucidated.
Methods Five-sixths nephrectomized (NX) rats received
either 0.4 lg/kg darbepoetin alfa (DA) weekly or 0.8 lg/kg
DA fortnightly between weeks 4 and 10. NX animals
receiving saline and a sham-operated (SHAM) group
served as controls. The levels of oxidized and reduced
glutathione (GSSG, GSH) were followed from blood
samples drawn fortnightly.
Results During the follow-up, the ratios GSSG/GSH
showed similar trends in both DA groups, levels being sig-
nificantly lower than those in the SHAM group at weeks 8
and 10. GSSG levels were lower than the baseline throughout
the study in all groups except for NX controls. The GSH
levels were increased in all three NX groups (weeks 6–10)
compared with both the baseline and the SHAM group
Conclusion Our results suggest that the extent of oxida-
tive stress is similar in response to different dosing regi-
mens of DA in 5/6 NX rats when comparable hemoglobin
levels are maintained. These findings remain to be con-
firmed in chronic kidney disease patients.
Keywords Chronic kidney disease  Erythropoiesis-
stimulating agent (ESA)  Erythropoietin  Glutathione 
Oxidative stress  Subtotal nephrectomy
Introduction
Erythropoiesis-stimulating agent (ESA) therapy plays a
fundamental role in the treatment of anemia in patients
with chronic kidney disease (CKD) [1, 2]. The develop-
ment of ESAs with longer serum half-lives relative to
recombinant human erythropoietin (EPO) has allowed an
extension of the intervals between administrations with an
unchanged or even decreased overall dose [3, 4]. For
example, darbepoetin alfa (DA) has been reported to
maintain stable hemoglobin (Hb) levels in hemodialysis
patients when given at fortnightly or weekly intervals
without changing the total dose [5].
Besides the erythropoietic properties of ESAs, their non-
hematopoietic effects are also extensively studied [6],
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including their roles in protection against ischemic injury
of various organs, and effects on the levels of oxidative
markers [7]. There are no data regarding the comparison of
the levels of oxidative stress during ESA therapy with dif-
ferent administration frequencies despite the clinical impor-
tance of this issue [3–5, 8]. To study this question, stable and
similar Hb levels are suggested in the groups with different
administration intervals, based on European [1] and American
[2] anemia treatment guidelines and the findings of our earlier
studies [9, 10]. We therefore induced comparable Hb levels
with two different frequencies of administration (but equal
overall doses) of DA in 5/6 nephrectomized (NX) rats, and
followed the changes in whole blood levels of oxidized and
reduced glutathione (GSSG and GSH, respectively).
Materials and methods
This study conformed to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (NIH Pub. No. 85-23, Revised 1996), and was
approved by the local ethics committee. Male Wistar rats
(n = 36, average body weight 300–320 g) were randomly
assigned to one or other of the following groups (n = 9–9):
a sham-operated group (SHAM); an NX control group; and
NX receiving DA (Amgen Inc., Thousand Oaks, CA, USA)
weekly or fortnightly (DA1 and DA2, respectively) (Fig. 1).
The animals were housed in individually ventilated cages
(Sealsafe IVC System, Buguggiate, Italy) with a 12:12 h
light:dark cycle, and had free access to standard rat chow
and water (containing 10 mg/kg body weight iron(II) sul-
fate). Five-sixths NX was performed in two steps by ligation
followed by surgical excision of both poles (1/3 on each
end) of the left kidney in the first step (baseline, week 1),
followed by removal of the right kidney 1 week later [11].
The rats were anesthetized with 60 mg/kg pentobarbital
sodium (Euthanyl, Bimeda-MTC Animal Health, Cam-
bridge, ON, Canada) during surgery. On the basis of the
results of a pilot study, uremia develops by week 4 in this
NX model (as shown by histological examination of the
remnant kidney and significant increases in plasma creati-
nine levels), and subsequent administrations of DA with
doses of 0.4 lg/kg weekly or 0.8 lg/kg fortnightly can
maintain comparable Hb levels for 6 weeks. Accordingly,
the subcutaneous administration of DA (DA1 group: 0.4 lg/
kg weekly; DA2 group: 0.8 lg/kg every other week) or
isotonic saline (weekly in both the SHAM and NX control
groups) was initiated at week 4 in the present study. At
week 10, DA was withdrawn and all animals received saline
(Fig. 1). The numbers of animals surviving at the end of the
12-week study were 9, 8, 7 and 8 in the SHAM, NX control,
DA1 and DA2 groups, respectively.
Blood samples (150–200 ll; anticoagulated with EDTA)
were obtained from the saphenous vein [12] (weeks 1, 4, 6,
8 and 10), or from the inferior caval vein (week 12), prior to
the administration of DA or saline. The whole blood Hb
levels were measured spectrophotometrically after reaction
with Drabkin’s reagent [13]. The whole blood GSSG and
GSH contents were determined essentially as published
earlier [14], with the modification that 1-methyl-2-vinylpy-
ridinium trifluoromethane sulfonate was used as thiol-
masking reagent instead of N-ethylmaleimide.
Statistical comparisons were performed by using repe-
ated-measures two-way analysis of variance (ANOVA),
followed by Bonferroni’s post-hoc test. Results are reported
as percentage changes in the basal values (mean ± SEM;
baseline = 100 %). p values \0.05 were considered
significant.
Fig. 1 Study protocol. NX
nephrectomized, DA
darbepoetin alfa
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Results
The Hb levels were increased relative to the baseline at
weeks 4 and 10 in the SHAM group (p \ 0.05), and were
decreased in the NX controls from week 8 compared with
both the baseline and the SHAM group (both p \ 0.05).
Apart from an elevation at week 10 in the DA1 group
(p \ 0.05), the Hb levels did not change significantly in the
DA-treated animals during the follow-up (Fig. 2).
Compared with the baseline, the ratios GSSG/GSH were
decreased between weeks 6–12 in all groups (weeks 6 and
12: p \ 0.05; weeks 8–10: p \ 0.01). The ratios in both
DA-treated groups were lower than those in the SHAM
group at weeks 8 and 10 (p \ 0.05, Fig. 3). The levels of
GSSG in the SHAM, DA1 and DA2 animals were lower
than the respective basal levels throughout the study. The
significance levels for the respective groups are as follows:
SHAM: p \ 0.05 (week 4) and p \ 0.001 (weeks 6–12);
DA1 and DA2: p \ 0.05 (weeks 4–6), p \ 0.001
(weeks 8–10) and p \ 0.01 (week 12). In the NX controls,
the GSSG concentrations were not significantly different
from the baseline, except for week 4 (p \ 0.05), and were
higher than those in the SHAM group between weeks 6–12
(p \ 0.01, Fig. 4). The GSH concentrations were decreased
at week 4 in all groups (p \ 0.01) compared with the
baseline, with elevations in all three NX groups between
weeks 6–10 relative both to the baseline (p \ 0.05 at
weeks 6 and 10; and p \ 0.01 at week 8) and to the SHAM
group (p \ 0.01 at weeks 6–10) (Fig. 5). The baseline val-
ues for the above parameters are summarized in Table 1.
Fig. 2 Hemoglobin levels in the study groups. Darbepoetin alfa
(DA1 and DA2 groups) or isotonic saline (SHAM and NX control
groups) administration was initiated at week 4. All animals received
saline from week 10. Data are presented as percentage changes in the
basal values (mean ± SEM; baseline = 100 %). Repeated-measures
two-way ANOVA and Bonferroni’s post-hoc test; n = 9, 8, 7 and 8 in
the SHAM, NX control, DA1 and DA2 groups, respectively. SHAM
group: filled squares and continuous lines; NX control group: filled
rhombuses and dashed lines; DA1 group: empty triangles and dotted
lines; DA2 group: empty circles and dashed-dotted lines. NX
nephrectomized. *p \ 0.05 versus the baseline; p \ 0.05 versus
the SHAM group
Fig. 3 Ratios of oxidized and reduced glutathione (GSSG/GSH) in
the study groups. Darbepoetin alfa (DA1 and DA2 groups) or isotonic
saline (SHAM and NX control groups) administration was initiated at
week 4. All animals received saline from week 10. Data are presented
as percentage changes in the basal values (mean ± SEM; base-
line = 100 %). **p \ 0.01 and *p \ 0.05 versus the baseline;
p \ 0.05 versus the SHAM group. Data on the statistical analyses
and symbols are the same as for Fig. 2
Fig. 4 Levels of oxidized glutathione (GSSG) in the study groups.
Darbepoetin alfa (DA1 and DA2 groups) or isotonic saline (SHAM
and NX control groups) administration was initiated at week 4. All
animals received saline from week 10. Data are presented as
percentage changes in the basal values (mean ± SEM; base-
line = 100 %). ***p \ 0.001, **p \ 0.01 and *p \ 0.05 versus the
baseline; p \ 0.01 versus the SHAM group. Data on the statistical
analyses and symbols are the same as for Fig. 2
Fig. 5 Levels of reduced glutathione (GSH) in the study groups.
Darbepoetin alfa (DA1 and DA2 groups) or isotonic saline (SHAM
and NX control groups) administration was initiated at week 4. All
animals received saline from week 10. Data are presented as
percentage changes in the basal values (mean ± SEM; base-
line = 100 %). **p \ 0.01 and *p \ 0.05 versus the baseline;
p \ 0.01 versus the SHAM group. Data on the statistical analyses
and symbols are the same as for Fig. 2
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Discussion
To the best of our knowledge, the present study is the first
to follow changes in oxidative stress markers during DA
therapy with two different administration frequencies in a
rat model of CKD. Similar trends in the levels of GSSG/
GSH and GSSG were found throughout the 12-week study
with weekly or fortnightly administrations of DA (Figs. 3,
4) when comparable Hb levels were maintained in the
groups. Further studies with larger cohorts and a parallel-
group or cross-over design, comparative studies using
ESAs other than DA, as well as assessment of other oxi-
dative stress markers are needed to confirm these findings
in patients with CKD.
Subtotal (mainly 5/6) NX is the most widely used model
of CKD in the rat [11]. The method of renal mass reduction
(i.e. surgical excision, or renal ablation by infarction) has a
substantial influence on the reproducibility of the proce-
dure, the surgical technique giving more reproducible
results [11]. In the present study, 2/3 NX of the left kidney
was performed in the first step, followed by removal of the
right kidney 1 week later [11, 15, 16]. Although the two
steps can be reversed [17], we opted for the above protocol
due to substantially longer survival of the animals in the
pilot study.
The production of reactive oxygen species and the levels
of oxidatively modified proteins were earlier reported to be
increased in subtotal NX rats [18], in accordance with the
present results of markedly higher levels of GSSG in the
NX controls than the SHAM group (Fig. 4). However,
levels of GSSG in the NX controls were not higher than the
respective baseline values. One possible explanation is the
finding of significant elevations in the GSH concentrations
in this group (Fig. 5), which could have counterbalanced
the pro-oxidant effect associated with NX, resulting in
similar ratios GSSG/GSH in both the NX control and
SHAM groups (Fig. 3). In a recent study, increased levels
of GSH after subtotal NX were related with an elevated
activity of glutamate-cysteine ligase (the rate-limiting
enzyme in GSH synthesis) [19]. Secondly, scavenger
activities of thiol moieties other than glutathione may also
play roles in the protection of oxidative stress in rats and
other species [20, 21], the assay of which, however, was
not performed in the present study. Therefore, it cannot be
excluded that such thiols played roles in the change in
oxidative stress.
In contrast, the GSSG levels in the two DA-treated
groups remained as low as in the SHAM group (Fig. 3),
resulting in significantly lower GSSG/GSH values at
weeks 8 and 10 compared with both the SHAM group and
the NX controls (Fig. 4). This result is in line with the
previously reported antioxidant effect of long-term ESA
treatment in CKD [7]. The mechanism of this effect is not
well understood [7]; further research is therefore needed in
this field. One of the proposed mechanisms is that EPO
stimulates cJun-N-terminal kinases (JNKs) in erythroid
cells [22], activating heme oxygenase-1 [23], thereby
contributing to the reduction of iron-dependent oxidative
injury [24]. One limitation of the present study is that
levels of iron-related serum parameters were not assayed.
Secondly, JNKs also stimulate Forkhead box class O
(FOXO) transcription factor FOXO3a [25], paralleled by
increases in survival and antioxidant capacity of the
erythrocytes [26, 27]. Finally, the proportions of reticulo-
cytes and young erythrocytes with high antioxidant
capacities and low levels of GSSG/GSH [28] are increased
during ESA therapy [29]. However, the actual proportions
of these cells were not determined in our study.
As concerns the withdrawal of DA at week 10 in the
present study, the ratios GSSG/GSH in the DA-treated
groups at week 12 tended to increase but the change did
not reach the level of significance (Fig. 3). In contrast, a
14-day withdrawal of epoetin beta was associated with a
marked increase in GSSG/GSH in hemodialysis patients in
our previous study [9]. Besides the different species
involved, the difference is probably also connected with the
fact that DA has a 3-fold longer serum half-life than that of
epoetin beta, allowing exposure of the erythroid cells to
DA for an extended period of time [29].
It may be speculated that the repeated blood sampling
might have affected the erythropoiesis to an extent which
could have compromised the results. It has been reported
Table 1 Baseline values of levels of hemoglobin, ratio of oxidized and reduced glutathione (GSSG/GSH), and oxidized and reduced glutathione
levels (GSSG and GSH, respectively) in the study groups
SHAM group NX controls DA1 group DA2 group
Hemoglobin (g/l) 139.6 ± 1.5 143.9 ± 2.5 146.4 ± 5.4 140.7 ± 2.0
GSSG/GSH (%) 0.38 ± 0.01 0.42 ± 0.02 0.39 ± 0.01 0.42 ± 0.02
GSSG (lmol/g Hb) 0.041 ± 0.001 0.043 ± 0.002 0.042 ± 0.001 0.046 ± 0.002
GSH (lmol/g Hb) 10.8 ± 0.3 10.2 ± 0.3 10.8 ± 0.4 10.9 ± 0.2
Data are presented as mean ± SEM. n = 9, 8, 7 and 8 in the SHAM, NX control, DA1 and DA2 groups, respectively
NX nephrectomized, DA darbepoetin alfa, Hb hemoglobin
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that a blood volume equivalent to about 0.5 % of the ani-
mal’s body weight can be drawn safely at fortnightly
intervals without disturbing the animal’s hematological
status [12]. In our study, the volume of 150–200 ll drawn
every other week corresponds to a maximum of about
0.05–0.07 % of the body weight (further decreasing with
time as animals grew). Thus, it is not likely that the
erythropoiesis was affected negatively by the blood sam-
pling protocol.
In summary, the changes in the levels of GSSG and
GSH during DA therapy administered at weekly or fort-
nightly intervals were followed in 5/6 NX rats for the first
time. The levels of GSSG/GSH and GSSG in the DA-
treated groups were lower than those in the NX controls, in
accordance with the reported antioxidant effects of ESA
treatment. When comparable Hb levels were maintained,
the level of oxidative stress did not differ in the groups
receiving different dosing regimens of DA, as revealed by
the similar trends in the levels of GSSG/GSH and GSSG.
These results remain to be confirmed in CKD patients and
in comparative studies involving other ESAs and assess-
ment of oxidative stress markers other than glutathione.
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